Canigen L4
Active substance
ATC code
Species
Dogs.
Indications
For active immunisation of dogs against:
- L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion
- L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion
- L. interrogans serogroup Australis serovar Bratislava to reduce infection
- L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
Dose to be administered and administration route
Subcutaneous use.
Before use, ensure that the vaccine is at room temperature (15 °C – 25 °C).
Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.
Vaccination schedule:
Primary vaccination:
The first vaccination can be administered from 6 to 9(*) weeks of age and the second vaccination from 10 to 13 weeks of age.
Revaccination:
Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine.
(*) In case of high level of maternally derived antibodies, first vaccination is recommended at 9 weeks of age.
For simultaneous use, 1 dose of a Canigen vaccine containing canine distemper virus, canine adenovirus type 2, canine parvovirus (strain 154) and/or canine parainfluenza virus components should be reconstituted with 1 dose (1 ml) of this vaccine. The mixed vaccines should be at room temperature (15 °C – 25 °C) before they are administered by subcutaneous injection.
Adverse reactions
Dogs:
|
Very common (>1 animal / 10 animals treated): |
Injection site swelling[1], Injection site nodule1, Injection site pain[2], Elevated temperature[3], Decreased activity4, Decreased appetite4. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Hypersensitivity reactions5, Immune mediated haemolytic anaemia, Immune mediated thrombocytopenia, Immune mediated polyarthritis. |
1 ≤ 4 cm; subsides within 14 days.
2 Subsides within 14 days.
3 ≤ 1 °C, up to 3 days.
4 In pups.
5 Reactions are transient. This includes anaphylaxis (sometimes fatal). If such reaction occurs, appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.
